Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma

Lung Cancer

Volumn 60, Issue 1, 2008, Pages 83-91

  Shin, Su Jin ^a   Kim, Hawk ^a   Baek, Jin Ho ^a   Ahn, Jong Joon ^a   Jegal, Yangjin ^a   Seo, Kwang Won ^a   Park, Chang Ryul ^a   Shin, Je Kyoun ^a   Jung, Jong Pil ^a   Kim, Jeong Won ^a   Cha, Hee Jeong ^a   Kwon, Woon Jung ^a   Jeong, Ae Kyung ^a   Noh, Young Ju ^a   Park, Jae Hoo ^a   Min, Young Joo ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Chemotherapy; Cisplatin; Fixed dose rate; Gemcitabine; Non small cell lung cancer; Uracil tegafur

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CISPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; UFT;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOLOGY; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC TOXICITY; HISTOLOGY; HUMAN; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TEGAFUR; URACIL;

EID: 41149176186     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.09.013     Document Type: Article

References (45)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2 (2001) 533-543
2. Lee C., Kang K.H., Koh Y., Chang J., Chung H.S., Park S.K., et al. Characteristics of lung cancer in Korea 1997. Lung Cancer 30 (2000) 15-22
3. Carbone D.P., and Minna J.D. Chemotherapy for non-small-cell lung cancer. BMJ 311 (1995) 889-890
4. Cullen M.H., Billingham L.J., Woodroffe C.M., Chetiyawardana A.D., Gower N.H., Joshi R., et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17 (1999) 3188-3194
5. Stephens R.F.D., and Gower N. The big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with NSCLC. Preliminary results in the supportive care setting. Proc Am Soc Clin Oncol 21 (2002) 291a (abstract 1161)
6. Crino L., and Cappuzzo F. Present and future treatment of advanced non-small-cell lung cancer. Semin Oncol 29 (2002) 9-16
7. Le Chevalier T., Brisgand D., Douillard J.Y., Pujol J.L., Alberola V., Monnier A., et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12 (1994) 360-367
8. Cardenal F., Lopez-Cabrerizo M.P., Anton A., Alberola V., Massuti B., Carrato A., et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17 (1999) 12-18
9. Grigorescu A.C., Draghici I.N., Nitipir C., Gutulescu N., and Corlan E. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial. Lung Cancer 37 (2002) 9-14
10. Negoro S., Masuda N., Takada Y., Sugiura T., Kudoh S., Katakami N., et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 88 (2003) 335-341
11. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
12. Peters G.J.B.A., and Ruiz van Haperen V.W.T. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol (1995) 22
13. Braakhuis B.J., Ruiz Van Haperen V.W.T., and Bergman A.M. Preclinical in vico evaluation of the combination of 2′,2′-difluorodeoxycytidine and cisplatin. Ann Oncol 5 Suppl 5 (1994) 82
14. Steward W.P., Dunlop D.J., Dabouis G., Lacroix H., and Talbot D. Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small-cell lung cancer: preliminary results. Semin Oncol 23 (1996) 43-47
15. Abratt R.P., Bezwoda W.R., Goedhals L., and Hacking D.J. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 15 (1997) 744-749
16. Crino L., Scagliotti G., Marangolo M., Figoli F., Clerici M., De Marinis F., et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 15 (1997) 297-303
17. Crino L., Scagliotti G.V., Ricci S., De Marinis F., Rinaldi M., Gridelli C., et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17 (1999) 3522-3530
18. Sandler A.B., Nemunaitis J., Denham C., von Pawel J., Cormier Y., Gatzemeier U., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18 (2000) 122-130
19. Anton A., Diaz-Fernandez N., Gonzalez Larriba J.L., Vadell C., Masutti B., Montalar J., et al. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small-cell lung cancer (NSCLC). Lung Cancer 22 (1998) 139-148
20. Tempero M., Plunkett W., Ruiz Van Haperen V., Hainsworth J., Hochster H., Lenzi R., et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21 (2003) 3402-3408
21. Brand R.C.M., and Tempero M. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 15 (1997) 331-341
22. Fujii S., Kitano S., Ikenaka K., and Shirasaka T. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann 70 (1979) 209-214
23. Ho D.H., Pazdur R., Covington W., Brown N., Huo Y.Y., Lassere Y., et al. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2′-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res 4 (1998) 2085-2088
24. Kato H., Ichinose Y., Ohta M., Hata E., Tsubota N., Tada H., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350 (2004) 1713-1721
25. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
26. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 (1982) 649-655
27. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10 (1989) 1-10
28. Ramalingam S., and Belani C.P. State-of-the-art chemotherapy for advanced non-small-cell lung cancer. Semin Oncol 31 (2004) 68-74
29. Abratt R.P., and Hart G.J. 10-year update on chemotherapy for non-small-cell lung cancer. Ann Oncol 17 Suppl 5 (2006) v33-v36
30. Comella P., Filippelli G., De Cataldis G., Massidda B., Frasci G., Maiorino L., et al. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Ann Oncol 18 (2007) 324-330
31. Paccagnella A., Oniga F., Bearz A., Favaretto A., Clerici M., Barbieri F., et al. Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study. J Clin Oncol 24 (2006) 681-687
32. Pratesi G., Gianni L., Manzotti C., and Zunino F. Sequence dependence of the anti-tumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice. Cancer Chemother Pharmacol 21 (1988) 237-240
33. Kuroki M., Nakano S., Mitsugi K., Ichinose I., Anzai K., Nakamura M., et al. In vivo comparative therapeutic study of optimal administration of 5-fluorouracil and cisplatin using a newly established HST-1 human squamous-carcinoma cell line. Cancer Chemother Pharmacol 29 (1992) 273-276
34. Yonekura K., Basaki Y., Chikahisa L., Okabe S., Hashimoto A., Miyadera K., et al. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res 5 (1999) 2185-2191
35. Dubey S., and Schiller J.H. Chemotherapy for advanced non-small-cell lung cancer. Hematol Oncol Clin North Am 18 (2004) 101-114
36. Kiura K., Takigawa N., Segawa Y., Tabata M., Shibayama T., Gemba K., et al. Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small-cell lung cancer: a phase I/II trial. J Thorac Oncol 2 (2007) 44-50
37. Scagliotti G.V., De Marinis F., Rinaldi M., Crino L., Gridelli C., Ricci S., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20 (2002) 4285-4291
38. Smit E.F., van Meerbeeck J.P., Lianes P., Debruyne C., Legrand C., Schramel F., et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. J Clin Oncol 21 (2003) 3909-3917
39. Le Chevalier T., Scagliotti G., Natale R., Danson S., Rosell R., Stahel R., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47 (2005) 69-80
40. Ceribelli A., Gridelli C., De Marinis F., Fabi A., Gamucci T., Cortesi E., et al. Prolonged gemcitabine infusion in advanced non-small-cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin. Cancer 98 (2003) 337-343
41. Cappuzzo F., Novello S., De Marinis F., Selvaggi G., Scagliotti G.V., Barbieri F., et al. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. Lung Cancer 52 (2006) 319-325
42. Ichinose Y., Takanashi N., Yano T., Asoh H., Yokoyama H., Tayama K., et al. A phase II trial of oral tegafur and uracil plus cisplatin in patients with inoperable non-small-cell lung cancer. Cancer 75 (1995) 2677-2680
43. Saito J., Nakai Y., Saijo Y., Nukiwa T., Koinumaru S., Matsuura Y., et al. A phase II trial of oral UFT plus cisplatin (CDDP) in patients with non-small-cell lung cancer (NSCLC). Lung Cancer 31 (2001) 285-293
44. Ichinose Y., Yosimori K., Yoneda S., Kuba M., Kudoh S., and Niitani H. UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced non-small-cell lung carcinoma: a multi-institutional phase II trial. For the Japan UFT Lung Cancer Study Group. Cancer 88 (2000) 318-323
45. Ichinose Y., Yano T., Kudoh S., Yoshimori K., Morikawa T., Kuba M., et al. UFT plus cisplatin in advanced non-small-cell lung cancer: interim analysis of 67 patients. Oncology (Williston Park) 11 (1997) 103-105